대동맥 스텐트 그래프트 시장 : 동맥류 부위별, 그래프트 유형별, 구성별, 전개 메커니즘별, 최종 사용자별, 액세스 경로별, 소재별 - 시장 예측(2026-2032년)

The Aortic Stent Grafts Market was valued at USD 1.13 billion in 2025 and is projected to grow to USD 1.21 billion in 2026, with a CAGR of 6.62%, reaching USD 1.78 billion by 2032.

An authoritative orientation to the current aortic stent graft ecosystem and the strategic imperatives that should guide medtech leaders and clinical stakeholders

The aortic stent graft sector occupies a critical juncture at the intersection of advancing device technology, shifting clinical practice patterns, and heightened scrutiny on cost and outcomes. Clinicians increasingly favor minimally invasive endovascular therapies for a broadening set of aortic pathologies, while device developers pursue platform innovations that improve conformability, seal, and branch vessel preservation. At the same time, hospitals and ambulatory surgical centers are recalibrating procurement frameworks to balance procedural throughput with durable clinical results.

This introduction frames the principal forces shaping product development, clinical adoption, and commercial strategy. It synthesizes recent regulatory milestones, emergent clinical evidence, and supply chain considerations that now inform go-to-market decisions. Readers will gain an actionable orientation to the priority challenges and opportunities facing manufacturers, providers, and payers, enabling clearer alignment of R&D, commercial, and policy objectives as they plan for the short and medium term.

In the sections that follow, the report distills structural shifts across technology, reimbursement environments, and geography, then translates those observations into segmentation, regional, and competitive insights designed to inform investment and product strategy decisions.

Transformative shifts reshaping clinical practice, product design, and commercial models in aortic therapeutics

The landscape of aortic stent grafts is being reshaped by several convergent trends that alter how devices are designed, evaluated, and adopted. First, device architectures are moving toward greater anatomic customization, with more complex branched and fenestrated solutions enabling treatment of previously inoperable anatomies. This trend is complemented by advances in delivery systems that improve navigability and lower profile, which together expand the procedural candidacy across patient cohorts. Simultaneously, the accumulation of long-term clinical data and real-world evidence has strengthened the value proposition of endovascular repair versus open surgery for selected aneurysm types, prompting care pathways to prioritize minimally invasive options where outcomes and access permit.

On the commercial front, procurement strategies are becoming more value-driven; hospitals and ambulatory surgical centers increasingly require evidence of cost-effectiveness, device longevity, and post-market surveillance commitments. This has elevated the importance of lifecycle data and post-approval studies, encouraging manufacturers to invest in registries and partnerships with clinical centers. Supply chain resilience has also become a strategic priority, with manufacturers reassessing supplier concentration, dual sourcing critical components, and exploring regional manufacturing footprints to mitigate disruption risks. Collectively, these shifts are driving a more integrated approach to innovation, where clinical evidence generation, manufacturing robustness, and commercial alignment are no longer sequential priorities but simultaneous imperatives.

Cumulative impact of recent United States tariff actions on clinical supply chains and manufacturer strategies

Recent tariff actions affecting medical device components and finished products have introduced new cost and operational dynamics for device manufacturers and health systems. Tariff-induced increases in input costs have prompted manufacturers to reassess sourcing strategies, shifting production emphasis toward regions with more predictable trade terms or to diversify suppliers to hedge against tariff volatility. This reconfiguration has implications for lead times, inventory carrying, and supplier qualification timelines, creating near-term pressures on supply continuity that require proactive mitigation by procurement teams.

Clinicians and hospital administrators have felt the downstream effects through tighter negotiation cycles and heightened scrutiny of total procedure costs. In response, some manufacturers have pursued margin protection strategies that include selective regional pricing adjustments, renegotiated supplier contracts, and targeted product bundling that rationalizes inventory. At the same time, providers have accelerated efforts to validate suppliers' long-term commitments to service levels and warranty performance, since supply disruptions can threaten elective procedure scheduling.

Regulatory and compliance teams are adapting to tariff-related documentation and classification challenges, which can slow customs clearance and add administrative overhead. To manage these effects, forward-looking organizations are investing in scenario planning, flexible manufacturing arrangements, and closer collaboration between commercial strategy and operations to preserve clinical access while navigating the shifting trade landscape.

Key segmentation insights drawing on anatomic, device, procedural, and end-user distinctions that structure clinical and commercial strategy

The market for aortic stent grafts fragments along multiple clinically meaningful dimensions that shape product requirements and go-to-market strategies. Aneurysm location is a primary determinant, separating abdominal aortic aneurysm from thoracic aortic aneurysm and thoracoabdominal aortic aneurysm, with each anatomic subset presenting distinct access, sealing, and branch preservation challenges. Within these categories, the clinical urgency differentiates elective repair cases from emergency repair scenarios, influencing device inventory needs, on-shelf availability, and training imperatives for rapid deployment.

Graft type drives technical differentiation and clinical value, with branched stent grafts and fenestrated stent grafts tailored to complex, branch-involving anatomies, while standard stent grafts address more straightforward profiles and often prioritize ease of delivery. Configuration nuances such as aorto-uni-iliac, bifurcated, and cuff designs determine fixation mechanics and compatibility with adjunctive devices, shaping both procedure planning and post-procedural surveillance. Deployment mechanics separate balloon expandable systems from self expanding platforms, each conferring trade-offs in radial force, conformability, and delivery sheath size that affect case selection and operator preference.

End-user setting exerts a profound influence on procurement cycles and support models, as ambulatory surgical centers prioritize throughput and device simplicity, whereas hospitals manage a broader mix of elective and emergency volumes requiring diverse inventory. Access route choices, notably iliac versus transfemoral approaches, steer product profile requirements and anatomical constraints. Finally, material selection such as expanded polytetrafluoroethylene versus polyester fabrics impacts long-term durability, thrombogenicity considerations, and regulatory dossier composition. Taken together, these segmentation axes demand that manufacturers align portfolio breadth with clinical training programs and targeted evidence to support adoption across heterogeneous care settings.

Regional dynamics that inform differentiated commercialization and clinical adoption approaches across major global markets

Regional dynamics shape how technologies are adopted, regulated, and purchased, requiring tailored strategies for each geography. The Americas market exhibits a strong emphasis on clinical evidence and reimbursement alignment, with hospitals and high-volume centers often acting as early adopters for complex branched and fenestrated systems. In contrast, Europe, Middle East & Africa displays heterogeneous adoption rates driven by national procurement protocols, variable reimbursement environments, and widely differing hospital infrastructures, which together create both pockets of advanced uptake and regions where cost and access constraints limit penetration.

Asia-Pacific markets present a diverse set of opportunities, where rapid hospital expansion and increasing investment in minimally invasive surgery are driving demand for a wider array of device configurations, yet local regulatory pathways and preferences for cost-competitive solutions shape purchasing choices. Across all regions, logistical considerations such as customs processes, regional distributor capabilities, and local training capacity materially influence time-to-adoption. Consequently, manufacturers that combine robust clinical support, adaptable pricing models, and regional supply chain resilience are better positioned to capture sustained uptake across these varied markets.

Competitive landscape insights highlighting strategic behaviors, capability gaps, and partnership opportunities among device manufacturers and ecosystem partners

Leading companies continue to compete on a combination of technical differentiation, clinical evidence, and service-level guarantees. Product roadmaps increasingly emphasize modularity and anatomical customization to capture complex anatomies, while other manufacturers concentrate on low-profile delivery systems and simplified deployment to address high-volume elective programs. Strategic behaviors also include targeted acquisitions to fill capability gaps in branched or fenestrated technologies, as well as licensing arrangements and co-development agreements designed to accelerate time to market for specialized solutions.

Emerging entrants often leverage narrow innovation niches-improved fixation mechanisms, novel fabric technologies, or advanced imaging integration-to gain clinical footholds, but scaling those innovations requires robust clinical partnerships and distribution capabilities. Established players retain advantages in global regulatory experience, manufacturing scale, and installed clinical support networks, yet they face pressure to demonstrate post-market outcomes and cost-effectiveness. There is growing evidence of collaborative models where manufacturers, clinical centers, and payers co-design registries and long-term follow-up studies to validate real-world performance and support reimbursement discussions. Overall, the competitive dynamic rewards organizations that pair technical differentiation with operational excellence and credible long-term evidence commitments.

Actionable recommendations that industry leaders can implement to enhance resilience, accelerate adoption, and maximize clinical impact

Manufacturers should prioritize modular product platforms that can address a spectrum of anatomic challenges while enabling manufacturing efficiency and inventory rationalization. Investing in comprehensive clinical evidence generation, including prospective registries and pragmatic real-world studies, will strengthen value propositions with hospitals and payers and reduce barriers to adoption. Operationally, diversifying critical component suppliers and exploring regional manufacturing or contract manufacturing partnerships can reduce tariff and logistics exposure while improving responsiveness to local demand.

Commercial teams should design differentiated go-to-market approaches for hospitals versus ambulatory surgical centers, aligning training, inventory models, and post-procedural support accordingly. Strategic collaborations with high-volume clinical centers to build centers of excellence and targeted training curricula can shorten adoption curves. Finally, engaging early with health economics experts and payer stakeholders to build clear reimbursement narratives will be essential for securing formulary placement and unit uptake, particularly for higher-cost branched and fenestrated solutions that deliver demonstrable downstream value.

Research methodology and evidence synthesis approach used to evaluate clinical, commercial, and regulatory dimensions of aortic stent grafts

The analysis integrates a mixed-methods research design that synthesizes primary qualitative inputs with comprehensive secondary evidence. Primary engagement included structured interviews with clinicians, hospital procurement leaders, and device development experts to capture practice patterns, device preferences, and procurement sensitivities. These qualitative insights were triangulated with secondary sources including peer-reviewed clinical literature, public regulatory filings, device labeling, clinical trial registries, and institutional guidelines to validate technical claims and clinical performance narratives.

Data synthesis emphasized cross-validation across independent sources and the use of scenario analysis to assess the robustness of strategic conclusions under varying operational assumptions. Where available, post-market surveillance summaries and registry data were used to contextualize durability and safety profiles. The methodology also incorporated rigorous segmentation mapping to align device features with clinical use-cases and buyer archetypes. Throughout, the approach aimed to balance depth of clinical insight with practical commercial implications to deliver a usable framework for decision-making.

Conclusion synthesizing strategic implications for stakeholders across clinical, commercial, and operational domains

The aortic stent graft sector is advancing into a phase where technical complexity, evidence demands, and supply chain resilience jointly define competitive advantage. Success will hinge on the ability to deliver devices that match increasingly sophisticated anatomic requirements while simultaneously demonstrating real-world outcomes and cost-effectiveness. Organizations that integrate R&D advances with rigorous evidence programs and resilient operational strategies will be best positioned to meet clinician expectations and procurement demands.

Looking forward, the interplay between evolving clinical indications, tariff and trade pressures, and regional adoption heterogeneity will create both challenges and opportunities. Firms that adopt a disciplined approach to segmentation, prioritize high-impact clinical partnerships, and build flexible manufacturing and distribution models will be able to accelerate adoption across diverse care settings. The actionable recommendations provided here are intended to guide leaders in aligning product portfolios, evidence generation, and operational capabilities to capture the long-term value potential inherent in modern aortic therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic Stent Grafts Market, by Aneurysm Location

• 8.1. Abdominal Aortic Aneurysm
• 8.2. Thoracic Aortic Aneurysm
• 8.3. Thoracoabdominal Aortic Aneurysm

9. Aortic Stent Grafts Market, by Graft Type

• 9.1. Branched Stent Graft
• 9.2. Fenestrated Stent Graft
• 9.3. Standard Stent Graft

10. Aortic Stent Grafts Market, by Configuration

• 10.1. Aorto-Uni-Iliac
• 10.2. Bifurcated
• 10.3. Cuff

11. Aortic Stent Grafts Market, by Deployment Mechanism

• 11.1. Balloon Expandable
• 11.2. Self Expanding

12. Aortic Stent Grafts Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Hospitals

13. Aortic Stent Grafts Market, by Access Route

• 13.1. Iliac
• 13.2. Transfemoral

14. Aortic Stent Grafts Market, by Material

• 14.1. Expanded Polytetrafluoroethylene
• 14.2. Polyester

15. Aortic Stent Grafts Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Aortic Stent Grafts Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Aortic Stent Grafts Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. United States Aortic Stent Grafts Market

19. China Aortic Stent Grafts Market

20. Competitive Landscape

• 20.1. Market Concentration Analysis, 2025
  • 20.1.1. Concentration Ratio (CR)
  • 20.1.2. Herfindahl Hirschman Index (HHI)
• 20.2. Recent Developments & Impact Analysis, 2025
• 20.3. Product Portfolio Analysis, 2025
• 20.4. Benchmarking Analysis, 2025
• 20.5. Abbott Laboratories
• 20.6. Aortec Medical Technology Co., Ltd
• 20.7. Aptus Endosystems, Inc.
• 20.8. Artivion, Inc.
• 20.9. Becton, Dickinson and Company
• 20.10. Bentley InnoMed GmbH
• 20.11. Bolton Medical Inc.
• 20.12. Cardinal Health, Inc.
• 20.13. Cook Medical LLC
• 20.14. CryoLife, Inc.
• 20.15. Endologix, Inc.
• 20.16. Endospan Ltd
• 20.17. JOTEC GmbH
• 20.18. LifeTech Scientific Co., Ltd
• 20.19. Lombard Medical Ltd
• 20.20. Medtronic plc
• 20.21. Merit Medical Systems, Inc.
• 20.22. MicroPort Scientific Corporation
• 20.23. Terumo Corporation
• 20.24. W. L. Gore & Associates, Inc.